IVX-121 / AstraZeneca - LARVOL DELTA

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults. (PubMed, Hum Vaccin Immunother) - "For both age groups, IVX-121 induced nAbs against RSV A and B, which remained above baseline levels for at least 6 months. A second dose of IVX-121 in older adults elicited a modest increase in nAbs against RSV A but not RSV B. Overall, IVX-121 had a favorable safety profile and induced immune responses against RSV in young and older adults."

First-in-human • Journal • P1 data • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: Icosavax, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Jan 2023 ➔ Jan 2024

Trial completion • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - P1 | N=120 | Active, not recruiting | Sponsor: Icosavax, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Icosavax, Inc.

New P1 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections